ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

olaparib

Also written as “Olaparib”, “AZD2281” and “KU-0059436 (AZD2281)(PARP inhibitor)”.

Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Prostatic Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 6 companies.

Drug pageOlaparib: every studyMany companies study it; this page follows only the 76 they lead. All 323 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 10, 201576 company-led studies, 22 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca5915 open or runningphase 4since Jun 10, 2015Jun 27, 2007Apr 6, 2027phase 3 · NCT04421963
Merckits history only125 open or runningphase 3since Mar 29, 2018Aug 3, 2016May 5, 2027phase 3 · NCT04380636
Novartisits history only20 open or runningphase 3since Jan 25, 2021Jan 25, 2021none ahead
Boryung Pharmaceuticalits history only11 open or runningphase 1since Jul 7, 2025Jul 7, 2025none ahead
CSPC Pharmaceutical Groupits history only10 open or runningphase 1since Apr 7, 2024Apr 7, 2024none ahead
Daewoong Pharmaceuticalits history only11 open or runningphase 1since Jan 19, 2026Jan 19, 2026Mar 2027phase 1 · NCT07371104

Also a collaborator on its studies: Myriad Genetic Laboratories, Frontier Science & Technology Research Foundation, Hoffmann-La Roche, Myriad Genetics, Iqvia Pty, Covance, Theradex, Parexel and KuDOS Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Jun 27, 2007.

  1. Mar 12, 2018Phase 3 study in Ovarian NeoplasmsNCT03534453 · 225 enrolled · China, Malaysia
  2. May 14, 2018Phase 1 study in Malignant Solid TumorNCT03553108 · 18 enrolled · Belgium
  3. Sep 28, 2018Phase 3 study in Metastatic Castration-resistant Prostate CancerNCT03732820 · 895 enrolled · United States, Australia, Belgium and more
  4. Oct 15, 2018Phase 3 study in Ovarian NeoplasmsNCT03737643 · 1,407 enrolled · United States, Austria, Belgium and more
  5. Nov 27, 2018Phase 2 study in Non-small Cell Lung Cancer NSCLCNCT03775486 · 401 enrolled · United States, Belgium, Hungary and more
  6. Nov 13, 2019Phase 1 study in NeoplasmsNCT04236414 · 16 enrolled · Denmark, France, Germany and more
  7. Jan 21, 2020Phase 2 study in Ovarian NeoplasmsNCT04239014 · United States, Canada, Italy and more
  8. Feb 10, 2020Phase 3 study in Endometrial NeoplasmsNCT04269200 · 805 enrolled · United States, Australia, Belgium and more
  9. Mar 30, 2020Phase 4 study in Ovarian NeoplasmsNCT04330040 · 202 enrolled · India
  10. May 19, 2020Phase 3 study in Ovarian NeoplasmsNCT04421963 · 185 enrolled · United States, Belgium, Bulgaria and more
  11. Apr 20, 2021Phase 3 study in Ovarian NeoplasmsNCT04884360 · 366 enrolled · Chile, China, Colombia and more
  12. Dec 20, 2021Phase 3 study in Metastatic Castration-resistant Prostate CancerNCT05171816 · 110 enrolled · China
  13. Jul 5, 2022Phase 2 study in Breast NeoplasmsNCT05498155 · 50 enrolled · United States, Australia, Austria and more
  14. Jul 11, 2022Phase 4 study in Metastatic Castration-resistant Prostate CancerNCT05457257 · 43 enrolled · China

Ahead

  1. Apr 6, 2027Primary completion: phase 3 study in Ovarian NeoplasmsNCT04421963

TargetBeta

“PARP 1, 2 and 3 inhibitor”ChEMBL 37, by rule

Studies

All 59 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05457257Metastatic Castration-resistant Prostate Cancer · China4Active, not recruitingOct 22, 202443
NCT05498155Breast Neoplasms · United States, Australia, Austria and more2CompletedNov 20, 202450
NCT05171816Metastatic Castration-resistant Prostate Cancer · China3Active, not recruitingJan 22, 2024110
NCT04884360Ovarian Neoplasms · Chile, China, Colombia and more3Active, not recruitingJul 27, 2026366
NCT04421963Ovarian Neoplasms · United States, Belgium, Bulgaria and more3Active, not recruitingApr 6, 2027185
NCT04330040Ovarian Neoplasms · India4CompletedSep 30, 2022202
NCT04269200Endometrial Neoplasms · United States, Australia, Belgium and more3Active, not recruitingJul 8, 2024805
NCT04239014Ovarian Neoplasms · United States, Canada, Italy and more2WithdrawnJan 25, 20210
NCT04236414Neoplasms · Denmark, France, Germany and more1CompletedFeb 4, 202516
NCT03775486Non-small Cell Lung Cancer NSCLC · United States, Belgium, Hungary and more2Active, not recruitingJan 11, 2021401
NCT03737643Ovarian Neoplasms · United States, Austria, Belgium and more3Active, not recruitingMar 17, 20251,407
NCT03732820Metastatic Castration-resistant Prostate Cancer · United States, Australia, Belgium and more3Active, not recruitingJul 30, 2021895
NCT03553108Malignant Solid Tumor · Belgium1CompletedMar 12, 201918
NCT03534453Ovarian Neoplasms · China, Malaysia3CompletedJan 27, 2025225
NCT03459846Urinary Bladder Neoplasms · United States, Canada, Russia and more2Active, not recruitingOct 15, 2020154
NCT03402841Ovarian Neoplasms · Austria, Belgium, Bulgaria and more3CompletedOct 2, 2020279
NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more2Active, not recruitingSep 13, 2024528
NCT03286842HER2-ve Metastatic Breast Cancer · United States, Bulgaria, Canada and more3CompletedOct 8, 2021256
NCT03106987Carcinoma, Ovarian Epithelial · Belgium, Canada, Denmark and more3CompletedFeb 15, 2021220
NCT03022409Squamous Cell Carcinoma of Head and Neck · United States, France, Taiwan1CompletedJan 20, 202121
NCT02987543Metastatic Castration-resistant Prostate Cancer · United States, Argentina, Australia and more3CompletedJun 4, 2019387
NCT02983799Ovarian Neoplasms · United States, Canada2CompletedDec 3, 2020272
NCT02561832Breast Neoplasms · United States, Spain1TerminatedSep 30, 201615
NCT02476968BRCA or HRR+ Mutated Ovarian Cancer Patients · Bulgaria, Canada, Czechia and more4CompletedApr 17, 2020181
NCT02430311Advanced Solid Tumours · China1CompletedJul 27, 201636
NCT02392676Ovarian Neoplasms · United States, Korea, Republic of, Peru and more3WithdrawnJun 20190
NCT02282020Ovarian Neoplasms · United States, Argentina, Belgium and more3CompletedOct 10, 2018266
NCT02184195Pancreatic Neoplasms · United States, Australia, Belgium and more3CompletedJan 15, 2019154
NCT02093351Neoplasms · Belgium, Denmark, France and more1CompletedApr 30, 201579
NCT02032823Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMar 27, 20201,837
NCT02000622Breast Neoplasms · United States, Bulgaria, China and more3CompletedDec 9, 2016302
NCT01972217Prostatic Neoplasms · United States, Belgium, Canada and more2CompletedSep 22, 2017158
NCT01924533Stomach Neoplasms · China, Japan, Korea, Republic of and more3CompletedApr 4, 2016525
NCT01921140Neoplasms · Belgium, Denmark, Netherlands and more1CompletedApr 8, 201460
NCT01874353Ovarian Neoplasms · United States, Australia, Belgium and more3Active, not recruitingSep 19, 2016327
NCT01851265Neoplasms · Belgium, Netherlands, United Kingdom1CompletedOct 18, 201332
NCT01844986Pathologic Complete Response · United States, Australia, Brazil and more3Active, not recruitingMay 17, 2018450
NCT01813474Neoplasms · Japan1CompletedAug 31, 201623
NCT01078662Ovarian · United States, Australia, Germany and more2CompletedJul 31, 2012298
NCT01081951Ovarian Neoplasms · United States, Australia, Belgium and more2Active, not recruitingOct 10, 2011162
NCT01063517Stomach Neoplasms · Korea, Republic of2CompletedMay 11, 2012124
NCT00912743Colorectal Neoplasms · United States2CompletedMar 201233
NCT00819221Solid Tumors · Italy, Switzerland1TerminatedNov 30, 201144
NCT00782574Advanced Solid Tumors · United States, Spain1CompletedFeb 1, 201257
NCT00777582Solid Tumors · Australia, Belgium, Switzerland and more1Active, not recruitingFeb 6, 2009197
NCT00753545Ovarian Neoplasms · United States, Australia, Austria and more2CompletedJun 30, 2010265
NCT00710268Neoplasm Metastasis · United Kingdom1CompletedMar 200918
NCT00707707Breast Neoplasms · Australia, Austria, Belgium and more1CompletedNov 9, 200919
NCT00679783Ovarian Neoplasms · Canada2CompletedMar 26, 201099
NCT00633269Neoplasm Metastasis · United Kingdom1CompletedOct 20086
NCT00628251Ovarian Neoplasms · United States, Australia, Belgium and more2CompletedSep 15, 200997
NCT00572364Neoplasms · Japan1CompletedMar 200918
NCT00516802Melanoma Neoplasms · United States, United Kingdom1CompletedJan 200940
NCT00516724Triple Negative Metastatic Breast Cancer · Belgium, Netherlands, United Kingdom1CompletedJan 4, 2013189
NCT00516438Malignant Solid Tumors · United Kingdom1CompletedMar 200948
NCT00516373Ovarian Neoplasms · Belgium, Netherlands, Poland and more1CompletedDec 17, 200898
NCT00515866Pancreatic Neoplasms · United States, United Kingdom1CompletedOct 201168
NCT00494442Ovarian Neoplasms · United States, Australia, Germany and more2CompletedMar 17, 200958
NCT00494234Breast Neoplasms · United States, Australia, Canada and more2CompletedFeb 27, 200954

How it is read

Names in the registry

  • “Olaparib”, 38 entries
  • “olaparib”, 10 entries
  • “AZD2281”, 10 entries
  • “KU-0059436 (AZD2281)(PARP inhibitor)”, 10 entries
  • “Olaparib 300mg tablets”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.